Actavis receives FDA acceptance for Opana ER tablets Actavis.

Launch of generic AXERT tablets Actavis received acceptance for previously, and is marketing currently, Oxymorphone Hydrochloride Extended-discharge Tablets 7.5 mg and 15 mg. The Company is defending ongoing patent litigation initiated by Endo regarding the 7 currently.5 mg and 15 mg Tablets, and continues to be evaluating launch plans for the additional dosage strengths at the moment.S. Product sales of around $461 million, according to IMS Health data.. Actavis receives FDA acceptance for Opana ER tablets Actavis, Inc. today announced that it provides received acceptance from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Oxymorphone Hydrochloride Extended-launch Tablets, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg.Related StoriesNew research discovers high prevalence of HIV among pregnant refugee women in OntarioPregnant women with elevated blood-sugar levels more likely to possess babies with heart defectsHSS experts help identify lupus patients at increased risk of issue pregnanciesBoth Waldron and Wilsnack said the smaller effects on reproduction discovered among men may be because of the fact that ladies reach higher blood alcohol concentrations than men while consuming similar levels of alcohol – which may contribute to a stronger hyperlink between drinking and reproductive complications in women.